News
1Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2Division of Life Sciences and Medicine, Department of Urology, the First Affiliated ...
1State Key Laboratory of Oral and Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School and Hospital of ...
Novartis announced it will spend $23 billion to construct and expand facilities in the United States. The planned investment includes six new manufacturing plants, including two radioligand therapy ...
1The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom.
Katelyn M. Mullen; Jungeui Hong; Marc A. Attiyeh; Akimasa Hayashi; Hitomi Sakamoto; Zachary A. Kohutek; Caitlin A. McIntyre; Haochen Zhang; Alvin P. Makohon-Moore ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Bengaluru, India–based Biocon Biologics announced today that bevacizumab-nwgd (Jobevne), a biosimilar of bevacizumab (Avastin; Genentech), was approved by the FDA. Bevacizumab, which is given ...
Gretchen M. Alicea; Payal Patel; Marie E. Portuallo; Mitchell E. Fane; Meihan Wei; Yash Chhabra; Agrani Dixit; Alexis E. Carey; Vania Wang; Murilo R. Rocha; Reeti ...
1Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China. 2Department of Urology, Shanghai Changzheng Hospital, Naval Medical ...
Department of Anatomy and Cell biology, Rush University Medical Center, Chicago, Illinois.
Marc Michel; Maryam Heidary; Anissa Mechri; Kévin Da Silva; Marine Gorse; Victoria Dixon; Klaus von Grafenstein; Charline Bianchi; Caroline Hego; Aurore Rampanou ...
David Fandrei; Sabine Seiffert; Michael Rade; Susanne Rieprecht; Nico Gagelmann; Patrick Born; Thomas Wiemers; Heike Weidner; Markus Kreuz; Tamara Schassberger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results